핵의학

본문글자크기
  • [Nat Med.] PET으로 면역항암제반응평가 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.

    University of Groningen / de Vries EGE*

  • 출처
    Nat Med.
  • 등재일
    2018 Dec
  • 저널이슈번호
    24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26.
  • 내용

    바로가기  >

    Abstract
    Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of patients with several tumor types, but predicting patient benefit using approved diagnostics is inexact, as some patients with PD-L1-negative tumors also show clinical benefit1,2. Moreover, all biopsy-based tests are subject to the errors and limitations of invasive tissue collection3-11. Preclinical studies of positron-emission tomography (PET) imaging with antibodies to PD-L1 suggested that this imaging method might be an approach to selecting patients12,13. Such a technique, however, requires substantial clinical development and validation. Here we present the initial results from a first-in-human study to assess the feasibility of imaging with zirconium-89-labeled atezolizumab (anti-PD-L1), including biodistribution, and secondly test its potential to predict response to PD-L1 blockade (ClinicalTrials.gov identifiers NCT02453984 and NCT02478099). We imaged 22 patients across three tumor types before the start of atezolizumab therapy. The PET signal, a function of tracer exposure and target expression, was high in lymphoid tissues and at sites of inflammation. In tumors, uptake was generally high but heterogeneous, varying within and among lesions, patients, and tumor types. Intriguingly, clinical responses in our patients were better correlated with pretreatment PET signal than with immunohistochemistry- or RNA-sequencing-based predictive biomarkers, encouraging further development of molecular PET imaging for assessment of PD-L1 status and clinical response prediction.

     


    Author information

    Bensch F1, van der Veen EL1, Lub-de Hooge MN2,3, Jorritsma-Smit A2, Boellaard R3, Kok IC1, Oosting SF1, Schröder CP1, Hiltermann TJN4, van der Wekken AJ4, Groen HJM4, Kwee TC3, Elias SG5, Gietema JA1, Bohorquez SS6, de Crespigny A6, Williams SP6, Mancao C7, Brouwers AH3, Fine BM6, de Vries EGE8
    1
    Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
    2
    Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
    3
    Medical Imaging Center, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
    4
    Pulmonary Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
    5
    Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
    6
    Genentech, San Francisco, CA, USA.
    7
    Genentech, Basel, Switzerland.
    8
    Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. e.g.e.de.vries@umcg.nl.

  • 덧글달기
    덧글달기
       IP : 3.92.96.247

    등록